FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

Mode of Action

A highly selective, first-in-class sodium glucose cotransporter 2 (SGLT2) inhibitor9

The kidney plays a key role in maintaining the body’s glucose balance, reabsorbing approximately 180 g of glucose per day.10,11

FORXIGA® acts in the kidney via an insulin-independent mechanism of action9

FORXIGA® acts in the kidney via an insulin independent approach
FORXIGA® acts in the kidney via an insulin independent approach

In normal kidney function:

  • 90% of glucose is reabsorbed into the blood at the proximal tubule (by SGLT2)11


  • SGLT2 is selectively inhibited, reducing glucose reabsorption12
  • Excess glucose is excreted in the urine12

The glucose-lowering effect of SGLT2 inhibitors is dependent on renal function.1,13,14
Patients with FORXIGA® maintained renal function over 102 weeks.15

FORXIGA® is not recommended for use in patients with estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73m2.1 The efficacy of FORXIGA® is dependent on renal function, and efficacy is reduced in patients who have moderate renal impairment and likely absent in patients with severe renal impairment.1